EP1303612A2 - Antigenes de streptocoque - Google Patents

Antigenes de streptocoque

Info

Publication number
EP1303612A2
EP1303612A2 EP01949136A EP01949136A EP1303612A2 EP 1303612 A2 EP1303612 A2 EP 1303612A2 EP 01949136 A EP01949136 A EP 01949136A EP 01949136 A EP01949136 A EP 01949136A EP 1303612 A2 EP1303612 A2 EP 1303612A2
Authority
EP
European Patent Office
Prior art keywords
polypeptide
polynucleotide
bvh
chosen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01949136A
Other languages
German (de)
English (en)
Inventor
Josée Hamel
Catherine Ouellet
Nathalie Charland
Denis Martin
Bernard Brodeur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID BIOMEDICAL CORPORATION
Original Assignee
Shire BioChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire BioChem Inc filed Critical Shire BioChem Inc
Priority to EP10179497A priority Critical patent/EP2281891A3/fr
Publication of EP1303612A2 publication Critical patent/EP1303612A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention is related to antigens, epitopes and antibodies directed to these epitopes, more particularly polypeptide antigens of streptococcus pneumoniae pathogen which may be useful for prophylaxis, diagnostic or treatment of streptococcal infection.
  • S . pneumoniae is an important agent of disease in man especially among infants, the elderly and immunocompromised persons. It is a bacterium frequently isolated from patients with invasive diseases such as bacteraemia/septicaemia, pneumonia, meningitis with high morbidity and mortality throughout the world. Even with appropriate antibiotic therapy, pneumococcal infections still result in many deaths. Although the advent of antimicrobial drugs has reduced the overall mortality from pneumococcal disease, the presence of resistant pneumococcal organisms has become a major problem in the world today. Effective pneumococcal vaccines could have a major impact on the morbidity and mortality associated with S. pneumoniae disease. Such vaccines would also potentially be useful to prevent otitis media in infants and young children. -
  • pneumococcal capsular polysaccharide More than 80 pneumococcal capsular serotypes have been identified on the basis of antigenic differences.
  • the currently available pneumococcal vaccine comprising 23 capsular polysaccharides that most frequently caused disease, has significant shortcomings related primarily to the poor immunogenicity of some capsular polysaccharides, the diversity of the serotypes and the differences in the distribution of serotypes over time, geographic areas and age groups. In particular, the failure of existing vaccines and capsular conjugate vaccines currently in development to protect young children against all serotypes spurres evaluation of other S_ ⁇ pneumoniae components.
  • PCT WO 00/39299 describes polypeptides and polynucleotides encoding these polypeptides.
  • PCT WO 00/39299 demonstrates that polypeptides designated as BVH-3 and BVH-11 provide protection against fatal experimental infection with pneumococci.
  • Streptococcus antigens that may be used as components for the prophylaxis, diagnostic and/or therapy of Streptococcus infection.
  • An isolated polynucleotide comprising a polynucleotide chosen from;
  • A, B, D, E or H (c) a polynucleotide encoding a polypeptide having an amino sequence chosen from table A, B, D, E or H; or fragments, analogs or derivatives thereof; (d) a polynucleotide encoding a polypeptide chosen from: table A, B, D, E or H; (e) a polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from: table A, B, D,
  • Figure 1 is the DNA sequence of SP64 BVH-3 gene; SEQ ID NO: 1
  • Figure 3 is the DNA sequence of SP64 BVH-11 gene; SEQ ID NO: 3
  • Figure 4 is a DNA sequence containing the complete SP64 BVH-11 gene at nucleotides 45 to 2567;
  • Figure 5 is a DNA sequence containing the complete SP64 BVH- 11-2 gene at nucleotides 114 to 2630; SEQ ID NO: 5
  • Figure 6 is the amino acid sequence of SP64 BVH-3 polypeptide; SEQ ID NO: 6
  • Figure 7 is the amino acid sequence of SP64 BVH-11 polypeptide; SEQ ID NO: 7
  • Figure 8 is the amino acid sequence of SP64 BVH-11-2 polypeptide; SEQ ID NO: 8
  • Figure 9 is the DNA sequence of SP63 BVH-3 gene; SEQ ID NO: 9
  • Figure 10 is the amino acid sequence of SP63 BVH-3 polypeptide; SEQ ID NO: 10
  • Figure 11 is the amino acid sequence of 4D4.9 polypeptide; SEQ ID NO: 11
  • Figure 13 is the amino acid sequence of 7G11.9 polypeptide; SEQ ID NO: 13
  • Figure 14 is the amino * acid sequence of 4D3.4 polypeptide
  • Figure 15 is the amino acid sequence of 8E3.1 polypeptide
  • Figure 16 is the amino acid sequence of 1G2.2 polypeptide; SEQ ID NO: 16
  • Figure 17 is the ami ⁇ o acid sequence of 10C12.7 polypeptide; SEQ ID NO: 17
  • Figure 18 is the amino acid sequence of 14F6.3 polypeptide; SEQ ID NO: 18
  • Figure 19 is the amino acid sequence of B12D8.2 polypeptide; SEQ ID NO: 19
  • Figure 20 is the amino acid sequence of 7F4.1 polypeptide; SEQ ID NO: 20
  • Figure 21 is the amino acid sequence of 10D7.5 polypeptide; SEQ ID NO: 21
  • Figure 23 is the amino acid sequence of 11B8.4 polypeptide; SEQ ID NO: 23
  • Figure 24 is the amino acid sequence of Mab H11B-11B8 target epitope; SEQ ID 163
  • Figure 25 is a schematic representation of the BVH-3 gene as well as location of gene sequences coding for the full length and truncated polypeptides. : The relationships between DNA fragments are shown with respect to each other.
  • Figure 26 is a schematic representation of the BVH-11 gene as well as location of gene sequences coding for the full length and truncated polypeptides . The relationships between DNA fragments are shown with respect to each other.
  • Figure 27 is a schematic representation of the BVH-11-2 gene as well as location of gene sequences coding for the full length and truncated polypeptides. The relationships between DNA fragments are shown with respect to each other.
  • Figure 28 is a schematic representation of the BVH-3 protein and the location of internal and surface epitopes recognized by certain monoclonal antibodies.
  • Figure 29 is a schematic representation of the BVH-11-2 protein and the location of protective surface epitopes recognized by certain monoclonal antibodies.
  • Figure 30 is a map of . plasmid pURV22.HIS. Kan R , kanamycin- resistance coding region; cI857, bacteriophage ⁇ CI857 temperature-sensitive repressor gene; lambda pL, bacteriophage ⁇ transcription promotor; His-tag, 6-histidine coding region; terminator, Tl transcription terminator; ori, colEl origin of replication.
  • Figure 31 depicts the comparison of the amino acid sequences of BVH-3M (sp64) and BVH-3 (Sp63) proteins by using the program Clustal W from MacVector sequence analysis software
  • the present invention is concerned with polypeptides in which undesired portions have been deleted and/or modified in order to obtain a specific immune response.
  • the polypeptides when the undesired portion of the polypeptides are deleted or modified, the polypeptides have desired biological properties. This is surprising in view of the fact that some of these portions were described as being epitope bearing portion in the patent application PCT WO 98/18930. In other publications such as PCT WO 00/37105, portions identified as histidine triad and coil coiled regions were said to be of importance . The present inventors have found that variants of the polypeptide BVH-3 and BVH-11 in which certain portions were deleted and/or modified and chimeras of these polypeptides have biological properties and generate a specific immune response.
  • an isolated polynucleotide comprising a polynucleotide chosen from;
  • the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from table A, B, D, E, G or H or fragments, analogues or derivatives thereof.
  • the present invention provides an isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from table A, B, D, E, G or H or fragments, analogues or derivatives thereof.
  • the present invention relates to polypeptides characterised by the amino acid sequence chosen from table A, B, D, E, G or H or fragments, analogues or derivatives thereof .
  • the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from table A, B, D, E, G or H.
  • the present invention provides an isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from table A, B, D, E, G or H.
  • the present invention relates to polypeptides characterised by the amino acid sequence chosen from table A, B, D, E, G or H.
  • the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen . from table B, E or H or fragments, analogues or derivatives thereof.
  • the present invention provides an isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from B, E or H or fragments, analogues or derivatives thereof .
  • the present invention relates to polypeptides characterised by the amino acid sequence chosen 5 from table B, E or H or fragments, analogues or derivatives thereof .
  • the present invention provides an isolated polynucleotide encoding a polypeptide having at least 10 70% identity to a second polypeptide comprising a sequence chosen from table B, E or H.
  • the present invention provides an isolated polynucleotide encoding a polypeptide having at least 15. 95% identity to a second polypeptide comprising a sequence chosen from B, E or H.
  • the present invention relates to polypeptides characterised by the amino acid sequence chosen 0 from table B, E or H.
  • nucleotides encoding polypeptides and chimeric polypeptides are within the scope of the present invention. 5
  • polypeptides or chimeric polypeptides in accordance with the present invention are antigenic .
  • polypeptides or chimeric polypeptides in accordance with the present invention are immunogenic .
  • polypeptides or chimeric 5 polypeptides in accordance with the present invention can elicit an immune response in an individual.
  • the present invention also relates to polypeptides which are able to raise antibodies having binding specificity to the polypeptides or chimeric polypeptides of the present invention as defined above.
  • polypeptides of table A (BVH-3) or table D (BVH-11) comprise at least one epitope bearing portion.
  • the fragments of the polypeptides of the present invention will comprise one or more epitope bearing portion identified, in Table C and F.
  • the fragment will comprises at least 15 contiguous amino acid of the polypeptide of table C and F.
  • the fragment will comprises at least 20 contiguous amino acid of the polypeptide of table C and F.
  • the epitope bearing portion of the polypeptide of table A (BVH-3) comprises at least one polypeptide listed in. Table C.
  • the epitope bearing portion of the polypeptide of table B (BVH-11) comprises at least one polypeptide listed in Table F.
  • An antibody that " has binding specificity" is an antibody that recognises and binds the selected polypeptide but which does not substantially recognise and bind other molecules in a sample, such as a biological sample. Specific binding can be measured using an ELISA assay in which the selected polypeptide is used as an antigen.
  • fragments include those polypeptides in which one or more of. the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably conserved) and which may be natural or unnatural.
  • derivatives and analogues of polypeptides of the invention will have about 70% identity with those sequences illustrated in the figures or fragments thereof. That is, 70% of the residues are the same.
  • polypeptides will have greater than 75% homology.
  • polypeptides will have greater than 80% homology.
  • polypeptides will have greater than 85% homology.
  • polypeptides will have greater than 90% homology. In a further embodiment, polypeptides will have greater than 95% homology. In a further embodiment, polypeptides will have greater than 99% homology. In a further embodiment, derivatives and analogues of polypeptides of the invention will have less than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10. Preferred substitutions are those known in the art as conserved i.e. the substituted residues share physical, or chemical properties such as hydrophobicity, size, charge or functional groups.
  • proteins or polypeptides of the invention will also find use in the context of the present invention, i.e. as antigenic/immunogenic material.
  • proteins or polypeptides which include one or more additions, deletions, substitutions or the like are encompassed by the present invention.
  • This program compares amino acid sequences and -finds the optimal alignment by inserting spaces in either sequence as appropriate. It is possible to calculate amino acid identity or similarity (identity plus conservation of amino acid type) for an optimal alignment.
  • a program like BLASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus* possible to obtain a comparison where several regions of similarity are found, each having a different score. Both types of identity analysis are contemplated in the present invention.
  • the analogues or derivatives could be fusion proteins, incorporating moieties which render purification easier, for example by effectively tagging the desired protein or polypeptide, It may be necessary to remove the "tag” or it may be the case that the fusion protein itself retains sufficient antigenicity to be useful .
  • antigenic/immunogenic fragments of the proteins or polypeptides of the invention, or of analogues or derivatives thereof are provided.
  • the fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties.
  • the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a protein or polypeptide, analogue or derivative as described herein.
  • the key issue, once again, is that the fragment retains the antigenic/immunogenic properties .
  • analogues, derivatives and fragments possess at least a degree of the antigenicity/immunogenic of the protein or polypeptide from which they are derived.
  • polypeptides of the invention include both polypeptides and chimeric polypeptides.
  • polypeptides which have fused thereto other compounds which alter the polypeptides biological or pharmacological properties i.e. polyethylene glycol (PEG) to increase half-life; leader or secretory amino acid sequences
  • amino acid regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the different epitopes of the different streptococcus strains.
  • polypeptides of the present invention can be modified by terminal -NH 2 acylation (e.g. by acetylation, or thioglycolic acid amidation, terminal carboxy amidation, e.g. with ammonia or methylamine) to provide stability, increased hydrophobicity for linking or binding to a support or other molecule.
  • terminal -NH 2 acylation e.g. by acetylation, or thioglycolic acid amidation, terminal carboxy amidation, e.g. with ammonia or methylamine
  • hetero and homo polypeptide multimers of the polypeptide fragments, analogues and derivatives include, for example, one or more polypeptides that have been cross-linked with cross-linkers such as avidin/biotin, gluteraldehyde or dimethylsuperimidate.
  • polymeric forms also include polypeptides containing two or more tandem or inverted contiguous sequences, produced from multicistronic mRNAs generated by recombinant DNA technology.
  • a fragment, analogue or derivative of a polypeptide of the invention will comprise at least one antigenic region i.e. at least one epitope.
  • polypeptides may be utilised having bishaloacetyl groups, nitroarylhalides, or the like, where the reagents being specific for thio groups. Therefore, the link between two mercapto groups of the different peptides may be a single bond or may be composed. of a linking group of at least two, typically at least four, and not more than 16, but usually not more than about 14 carbon atoms.
  • polypeptide fragments, analogues and derivatives of the invention do not contain a methionine (Met) starting residue.
  • polypeptides will not incorporate a leader or secretory sequence (signal sequence) .
  • the signal portion of a polypeptide of the invention may be determined according to established molecular biological techniques.
  • the polypeptide of interest may be isolated from a streptococcus culture and subsequently sequenced to determine the initial residue of the mature protein and therefore the sequence of the mature polypeptide.
  • vaccine compositions comprising one or more streptococcus polypeptides of the invention in admixture with a pharmaceutically acceptable carrier diluent or adjuvant.
  • suitable adjuvants include oils. i.e. Freund's complete or incomplete adjuvant; salts i.e. A1K(S0 4 ) 2 , AlNa(S0 4 ) 2 , A1NH 4 (S0 4 ) 2 , silica, kaolin, carbon polynucleotides i.e. poly IC and poly AU.
  • Preferred adjuvants include QuilA and Alhydrogel .
  • Vaccines of the invention may be administered parenterally by injection, rapid infusion, nasopharyngeal absorption, dermoabsorption, or bucal or oral.
  • Pharmaceutically acceptable carriers also include tetanus toxoid.
  • vaccine is also meant to include antibodies.
  • one or more antibodies having binding specificity for the polypeptides of the present invention for the treatment or prophylaxis of streptococcus infection and/or diseases and symptoms mediated by streptococcus infection.
  • vaccine compositions of the present invention are used for the treatment or prophylaxis of meningitis, otitis media, bacteremia or pneumonia.
  • vaccine compositions of the invention are used for the treatment or prophylaxis of streptococcus infection and/or diseases and symptoms mediated by streptococcus infection, in particular S .pneumoniae, group A streptococcus (pyogenes) , group B streptococcus (GBS or agalactiae) , dysgalactiae, uberis, nocardia as well as Staphylococcus aureus .
  • the streptococcus infection is S .pneumoniae.
  • vaccines are administered to those individuals at risk of streptococcus infection such as infants, elderly and immunocompromised individuals.
  • the term " individuals" include mammals. In a further embodiment, the mammal is human.
  • Vaccine compositions are preferably in unit dosage form of about 0.001 to 100 ⁇ g/kg (antigen/body weight) and more preferably 0.01 to 10 ⁇ g/kg and most preferably 0.1 to 1 ⁇ g/kg 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.
  • Vaccine compositions are preferably in unit dosage form of about 0.1 ⁇ g to 10 mg and more preferably l ⁇ g to 1 mg and most preferably 10 to 100 ⁇ g 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.
  • polynucleotides encoding polypeptides characterised by the amino acid sequence chosen from table A, B, D, E, G or H or fragments, analogues or derivatives thereof.
  • polypeptides characterised by the amino acid sequence chosen from table B, E or H or fragments, analogues or derivatives thereof.
  • polynucleotides are those illustrated in table A, B, D, E, G or H which encodes polypeptides of the invention .
  • polynucleotide sequences illustrated in the figures may be altered with degenerate codons yet still encode the polypeptides of the invention. Accordingly the present invention further provides polynucleotides which hybridise to the polynucleotide sequences herein above described (or the complement sequences thereof) having 50% identity between sequences. In one embodiment, at least 70% identity between sequences. In one embodiment, at least 75% identity between sequences. In one embodiment, at least 80% identity between sequences. In one embodiment, at least 85% identity between sequences. In one embodiment, at least 90% identity between sequences. In a further embodiment, polynucleotides are hybridizable under stringent conditions i.e. having at least 95% identity. In a further embodiment, more than 97% identity.
  • Suitable stringent conditions for hybridation can be readily determined by one of skilled in the art (see for example Sambrook et al . , (1989) Molecular cloning : A Laboratory Manual, 2 nd ed, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology, (1999) Edited by Ausubel F.M. et al . , John Wiley & Sons, Inc., N.Y.).
  • the present invention provides polynucleotides that hybridise under stringent conditions to either (a) a DNA sequence encoding a polypeptide or
  • polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising a sequence chosen from table A, B, D, E, G or H or fragments or analogues thereof .
  • polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising a sequence chosen from table B, E or H or fragments or analogues thereof.
  • polynucleotides are those encoding polypeptides of the invention illustrated in table A, B, D, E, G or H. As will be readily appreciated by one skilled in the art, polynucleotides include both DNA and RNA.
  • the present invention also includes , polynucleotides complementary to the polynucleotides described in the present application.
  • polynucleotides encoding polypeptides of the invention, or fragments, analogues or derivatives thereof may be used ' in a DNA immunization method. That is, they can be incorporated into a vector which is replicable and expressible upon injection thereby producing the antigenic polypeptide in vivo.
  • polynucleotides may be incorporated into a plasmid vector under the control of the CMV promoter which is functional in eukaryotic cells.
  • the vector is injected intramuscularly.
  • host cells are • transfected with vectors which encode the polypeptide, and then cultured iri a nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes.
  • Suitable vectors are those that are viable and replicable in the chosen host and include chromosomal, non-chromosomal and synthetic DNA sequences e.g. bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA.
  • the polypeptide sequence may be incorporated in the vector * at the appropriate site using restriction enzymes such that it is operably linked to an expression control region comprising a promoter, ribosome binding site (consensus region or Shine-Dalgarno sequence) , and optionally an operator (control element) .
  • an expression control region comprising a promoter, ribosome binding site (consensus region or Shine-Dalgarno sequence) , and optionally an operator (control element) .
  • Suitable promoters include but are not limited to LTR or SV40 promoter, E.coli lac, tac or trp promoters and the phage lambda P L promoter.
  • Vectors will preferably incorporate an origin of replication as well as selection markers i.e. ampicilin resistance gene.
  • Suitable bacterial vectors include pET, pQE70, pQE60, pQE-9, pbs, pDIO phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNHl ⁇ A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 and eukaryotic vectors pBlueBacIII, pWLNEO, pSV2CAT, pOG44, pXTl, pSG, pSVK3 , pBPV, pMSG and pSVL.
  • Host cells may be bacterial i.e. E.coli, Bacillus subtilis, Streptomyces ; fungal i.e. Aspergillus niger, Aspergillus nidulins; yeast i.e. Saccharomyees or eukaryotic i.e. CHO, COS.
  • polypeptide Upon expression of the polypeptide in culture, cells are typically harvested by centrifugation then disrupted by physical or chemical means (if the expressed polypeptide is not secreted into the media) and the resulting crude extract retained to isolate the polypeptide of interest. Purification of the polypeptide from culture media or lysate may be achieved by established techniques depending on the properties of the polypeptide i.e. using ammonium sulfate or ethanol precipitation , acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography. Final purification may be achieved using HPLC.
  • the polypeptide may be expressed with or without a leader or secretion sequence.
  • the leader may be removed using post-translational processing (see US 4,431,739; US 4,425,437; and US 4,338,397 incorporated herein by reference) or be chemically removed subsequent to purifying the expressed polypeptide.
  • the streptococcus polypeptides of the invention may be used in a diagnostic test for streptococcus infection, in particular S . pneumoniae infection.
  • a diagnostic test for streptococcus infection in particular S . pneumoniae infection.
  • Several diagnostic methods are possible, for example detecting streptococcus organism in a biological sample, the following procedure may be followed: a) obtaining a biological sample from a patient; b) incubating an antibody or fragment thereof reactive with a streptococcus polypeptide of the invention with the biological sample to form a mixture; and c) detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of streptococcus .
  • a method for the detection of antibody specific to a streptococcus antigen in a biological sample containing or suspected of containing said antibody may be performed as follows: a) obtaining a biological sample from a patient; b) incubating one or more streptococcus polypeptides of the invention or fragments thereof with the biological sample to form a mixture; and c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to streptococcus .
  • this diagnostic test may take several forms, including an immunological test such as an enzyme-linked immunosorbent assay (ELISA) , a radioimmunoassay or a latex agglutination assay, essentially to determine whether antibodies specific for the polypeptide are present in an organism.
  • an immunological test such as an enzyme-linked immunosorbent assay (ELISA)
  • ELISA enzyme-linked immunosorbent assay
  • radioimmunoassay or a latex agglutination assay
  • the DNA sequences encoding polypeptides of the invention may also be used to design DNA probes for use in detecting the presence of streptococcus in a biological sample suspected of containing such bacteria.
  • the detection method of this invention comprises: a) obtaining the biological sample from a patient; b) incubating one or * more DNA probes having a DNA sequence encoding a polypeptide of the invention or fragments thereof with the biological sample to form a mixture; and c) detecting specifically bound DNA probe in the mixture which indicates the presence of streptococcus bacteria.
  • the DNA probes of this invention may also be used . for detecting circulating streptococcus i.e. S.pneumoniae nucleic acids in a sample, for example using a polymerase chain reaction, as a method of diagnosing streptococcus infections.
  • the probe may be synthesized using conventional techniques and may be immobilized on a solid phase, or may be labelled with a detectable label.
  • a preferred DNA probe for this application is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of the streptococcus pneumoniae polypeptides of the invention.
  • Another diagnostic method for the detection of streptococcus in a patient comprises: a) labelling an antibody reactive with a polypeptide of the invention or fragment thereof with a detectable label; b) administering the labelled antibody or labelled fragment to the patient; 'and c) detecting specifically bound labelled antibody or labelled fragment in the patient which indicates the presence of streptococcus .
  • a further aspect of the invention is the use- of the streptococcus polypeptides of the invention as immunogens for the production of specific antibodies for the diagnosis and in particular the treatment of streptococcus infection.
  • Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular antibody to passively protect against streptococcus infection in a test model.
  • an animal model is the mouse model described in the examples herein.
  • the antibody may be a whole antibody or an antigen-binding fragment thereof and may belong to any immunoglobulin class.
  • the antibody or fragment may be of animal origin, specifically of mammalian origin and more specifically of murine, rat or human origin.
  • the term recombinant antibody or antibody fragment means antibody or antibody fragment which was produced using molecular biology techniques.
  • the antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the streptococcus pneumoniae polypeptides but is preferably specific for one.
  • a further aspect of the invention is the use of the antibodies
  • Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular antibody to passively
  • L ⁇ protect against streptococcus infection in a test model.
  • an animal model is the mouse model described in the examples herein.
  • the antibody may be a whole antibody or an antigen-binding fragment thereof and may belong to any immunoglobulin class.
  • the antibody or fragment may be of
  • L5 animal origin specifically of mammalian origin and more specifically of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or if desired, a recombinant antibody or antibody fragment.
  • recombinant antibody or antibody fragment means antibody or
  • the antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the streptococcus pneumoniae polypeptides but is preferably specific for one.
  • the pURV22.HIS vector contains a cassette of the bacteriophage ⁇ cI857 temperature-sensitive repressor gene from which the functional P R promoter has been deleted.
  • the inactivation of the cI857 repressor by a temperature increase from the range of 30-37°C to 37-42°C results in the induction of the gene under the control of promoter ⁇ PL.
  • the PCR primers used for the generation of the recombinant plasmids had a restriction endonuclease site at the 5 'end, thereby allowing directional cloning of the amplified product into the digested plasmid vector.
  • the PCR oligonucleotide primers used are listed in the following Table 1. The location of the gene sequences coding for BVH-3, BVH-11 and BVH-11-2 gene products is summarized in the Figure 25, Figure 26 and Figure 27, respectively. Table 1. List of PCR oligonucleotide primers
  • PCR- anplified products were digested with restriction end ⁇ nucleases and ligated to either linearized plasmid pSL301, pCMV-G ⁇ , pET or pURV22.HIS expression vector digested likewise or digested with enzym ⁇ s that prcdnce compatible cohesive ends.
  • Recombinant pSL301 and recc ⁇ binant pCMV-GH plasmids were digested with restriction enzyrres for the in-fra ⁇ e cloning in pEI expression vector.
  • pET vectors When pET vectors were used, clones were first stabilized in coli EEE ⁇ before introducti ⁇ n into EL coli BL ⁇ l( ⁇ DE3) or AD494 ( ⁇ DE3) for expression of full- length or truncated BVH-3, BVH-11 or BVH-11-2 molecules.
  • Each of the resultant plasmid constructs was confirmed by nucleotide sequence analysis.
  • the rec ⁇ >inant proteins were expressed as N-terminal fusions with the thiored ⁇ xin and His-tag (pEI32 expression system) ; as C-terminal fusions with an His-tag (pEI21 expression system) ; or as N-terminal fusions with an His-tag (pUV22.HIS expression system) .
  • the expressed rec ⁇ rbinant proteins were purified fran supernatant fractions obtained after centrifugation of sonicated IPIG- (pET systems) or heat- (pURV22.HIS) induced EL coli using a His-Bind metal chelation resin. (QIAgen, Chatsworth, CA) .
  • the gene products generated fom £X pneumoniae SP64 are listed in the following Table 2.
  • the gene fragment encoding BVH-3- Sp63 protein (amino acid residues 21 to 840 on SEQ ID NO: 10) was generated from ___. pneumoniae SP63 using the PCR-primer sets OCRR479-OCRR480 and the cloning vector pSLBOl.
  • the reccnbinant pSL301-BVH-3Sp63 was digested for the in-frame cloning in p ⁇ I32 vector for the expression of the BVH-3-Sp63 molecule.
  • Monoclonal antibody (Mab) -secreting hybridomas were obtained by fusions of spleen cells from immunized mice and non-secreting, HGPRT-deficient mouse myeloma SP2/0 cells by the methods of Fazekas De St-Groth and Scheidegger (J Immunol Methods 35 : 1-21, 1980) with modifications (J. Hamel et al . J Med Microbiol 23 : 163-170, 1987) .
  • mice Female BALB/c mice (Charles River, St-Constant, Quebec, Canada) were immunized with either BVH-3M (thioredoxin- His*Tag-BVH-3M fusion protein/ pET32 system) , BVH-11M (thioredoxin-His * Tag-BVH-HM fusion protein/ pET32 system) , BVH-11-2M (thioredoxin-His»Tag-BVH-ll-2M fusion protein/ pET32 system) , BVH-11B (thioredoxin-His * Tag-BVH-llB fusion protein/ pET32 system) , BVH-3M (His «Tag-BVH-3 fusion protein/ pURV22.HIS system) or NE 1 (NEWl-His * Tag fusion protein/ pET21 system) gene products from S ⁇ pneumoniae strain SP64 to generate the Mab series H3-, H11-, H112-, HUB-, H3V- , and
  • BVH-3 and BVH-11 gene fragments corresponding to the 3 ' end of the genes were amplified by PCR using pairs of oligonucleotides engineered to amplify gene fragments to be included in the chimeric genes .
  • the primers used had a restriction endonuclease site at the 5' end, thereby allowing directional in-frame cloning of the amplified product into digested plasmid vectors (Table 1 and Table 2) .
  • PCR-amplified products were digested with restriction endonucleases and ligated to linearized plasmid pET21 or pSL301 vector. The resultant plasmid constructs were confirmed by nucleotide sequence analysis.
  • the recombinant pET21 plasmids containing a PCR product were linearized by digestion with restriction enzymes for the in-frame cloning of a second DNA fragment and the generation of a chimeric gene encoding for a chimeric pneumococcal protein molecule.
  • Recombinant pSL301 plasmids containing a PCR product were digested with restriction enzymes for the obtention of the DNA inserts.
  • the resulting insert DNA fragments were purified and inserts corresponding to a given chimeric gene were ligated into pET21 vector for the generation of a chimeric gene.
  • the recombinant chimeric polypeptides listed in Table 2 were as C-terminal fusion with an His-tag.
  • the expressed recombinant proteins were purified from supernatant fractions obtained from centrifugation of sonicated IPTG-induced E ⁇ coli cultures using a His-Bind metal chelation resin (QIAgen, Chatsworth, CA) .
  • mice Groups of 8 female BALB/c mice (Charles River) were immunized subcutaneously two times at three-week intervals with 25 ⁇ g of either affinity purified His»Tag-fusion protein identifed in presence of 15-20 ⁇ g of QuilA adjuvant. Ten to 14 days following the last immunization, the mice were challenged challenged intravenously with 10E5-10E6 CFU of S. pneumoniae type 3 strain WU2. The polypeptides and fragments are capable of eliciting a protective immune response.
  • Hybridomas were tested by ELISA against truncated BVH-3 , BVH- 11 or BVH-11-2 gene products in order to characterize the epitopes recognized by the Mabs.
  • the truncated gene products were generated from S_ ; _ pneumoniae SP64 strain except for BVH-
  • BVH-3- and BVH-11-cross-reactive Mabs were also reactive with BVH-11A and BVH-11-2M recombinant proteins.
  • BVH-3B-reactive Mabs can be subdivided into three subgroups according to their reactivity with NEW1, NEW2 and NEW3 recombinant proteins. Some Mabs were only reactive with the NEW1 protein while other Mabs were reactive with either, NEW1 and NEW2 or NEW1 and NEW3 recombinant proteins .
  • H11-7G11 and H3V-15A10 react with epitopes in more than one position on BVH-3.
  • the reactivity of H11-7G11 with BVH- 3AD, BVH-3B, BVH-3C, BVH-11A and BVH-11-2M molecules suggests that H11-7G11 epitope might comprised HXXHXH sequence. This sequence is repeated, respectively, 6 and 5 times in BVH-3 and BVH-ll/BVH-11-2 protein sequences.
  • the lack of reactivity of Mab H11-7G11 with NEW 10 molecule suggests that the epitope includes the HGDHXH sequence.
  • Multiple-position mapping of H3V-15A10 epitope on BVH-3 is suggested by the reactivity of the Mab with two BVH-3 fragments that do not overlap.
  • This example describes the construction of BVH-3 and BVH-11-2 gene libraries for the mapping of epitopes.
  • BVH-3 and BVH-11-2 gene libraries were constructed using recombinant pCMV-GH and PSL301 plasmid DNA containing respectively, BVH-3 gene sequence spanning nucleotides 1837 to 4909 (SEQ ID NO: 2) or BVH-11-2 gene sequence spanning nucleotides 172 to 2630 (SEQ ID NO: 5) and the Novatope ® library construction and screening system (Novagen) .
  • the recombinant plasmids containing BVH-3 or BVH-11-2 gene fragment were purified Using QIAgen kit (Chatsworth, CA) and digested with the restriction enzymes Bglll and Xbal respectively.
  • the resulting Bglll-Xbal DNA fragments were purified using the QIAq ⁇ ick gel extraction kit from QIAgen and digested with Dnase I for the generation of randomly cleaved DNA.
  • DNA fragments of 50 to 200 bp were purified, treated with T4 DNA polymerase to blunt the target DNA ends and add a single 3 ' dA residue, and ligated into pSCREEN-T-Vector (Novagen) following the procedures suggested by the manufacturer (Novatope ® System, Novagen) .
  • NZW rabbits (Charles River Laboratories, St-Constant, Quebec, Canada) were immunized subcutaneously at multiple sites with 50 ⁇ g or 100 ⁇ g of the purified BVH-3M, L-BVH-3AD, NEW1, NEW13, or L-BVH-11 recombinant protein in presence of 80 ⁇ g of QuilA adjuvant (Cedarlane Laboratoratories Ltd, Hornby, Canada) .
  • the rabbits were boosted two times at three-week intervals with the same antigen and blood samples were collected before each immunization and 6 to 28 days following the last immunization.
  • the sera samples were designated preimmune, post 1 st , post 2 nd or post 3 rd injection.
  • the rabbit immune response to immunization was evaluated by ELISA using recombinant BVH-3M (BVH-3M-His»Tag fusion protein/ pET21 system) or BVH-llM (BVH-llM-His «Tag fusion protein/ pET21 system) proteins or suspensions of heat-killed ⁇ S ⁇ pneumoniae Rx-1 cells as coating antigens.
  • ELISA titer was defined as the reciprocal of the highest sera dilution at which absorbance A 4io value was 0.1 above the background value .
  • Antibodies reactive with BVH-3 and/or BVH-11 epitopes were elicited following immunization in all animals as shown in the following Table 6.
  • Antibody reactive with recombinant or pneumococcal antigens was not present in the preimmune sera.
  • the immune response to immunization was detectable in the sera of each rabbit after a single injection of recombinant antigen.
  • the antibody response following the second injection with either antigen tested was characterized by a strong increase in antibody titer.
  • good titers of antibody reactive with S ⁇ pneumoniae cells, with an average titer of 52,000 after the third immunization were obtained, thus establishing that native pneumococcal epitopes are expressed on the recombinant E ⁇ coli gene products.
  • This example describes the protection of animals against fatal experimental pneumococcal infection by administration of antibody raised to BVH-3, BVH-11 or BVH-11-2 gene products.
  • the CBA/N mice were chosen because of their high susceptibility to S ⁇ pneumoniae infection.
  • the LD S0 of WU2 injected intravenously to CBA/N mice is estimated to be ⁇ 10 CFU. Deaths were recorded at 24-h intervals for a period of at least 7 days.
  • mice injected with rabbit anti-BVH-3 antibody are set forth in the following Table 7.
  • CBA/N ttiice were infected with 1000 CFU of WU2 S ⁇ pneumoniae before or after intraperitoneal administration of 0.1 ml of rabbit antibody.
  • mice 0.1 ml of rabbit antibody prepared from preimmune and immune sera were administered intraperitoneally to CBA/N mice four hours before intranasal challenge with 280 CFU of S ⁇ pneumoniae P4241 type 3 strain.
  • all immunized mice survived the challenge while none of 9 mice receiving preimmune sera antibody or buffer alone were alive on day 6 post-infection.
  • S . pneumoniae hemocultures on day 11 post-challenge were negative for all surviving mice.
  • 100% protection was observed in mice receiving monoclonal antibodies H112-10G9 or a mixture of H112-10G9 and H11B-7E11 which are directed against BVH-ll/BVH-11-2.
  • the protection data obtained for mice injected with ascites fluid are set forth in the following Table 9.
  • Administration of a volume of 0.2 ml of ascites fluid of 0.2 ml of some sets of ascites fluid prevented death from experimental infection.
  • H112-3A4 + H112-10G9 and H112-10G2 + H112-10D7 sets of 2 Mabs conferred complete protection against experimental infection.
  • the Mabs H112-3A4, H112-10G9, H112-10D7, H112- 10A2, H112-3E8, H112-10C5, H11B-11B8, H11B-15G2, H11B-1C9, H11B-7E11, H11B-13D5 and H11-10B8 were present in at least one protective pair of Mabs and were said to be protective and reactive against protective epitopes.
  • the locations of protection-conferring epitopes on BVH-11-2 molecules are summarized in Table 10 and Figure 29 .
  • Protective Mabs H112- 3A4, H112-10G9, H112-10D7, H112-10A2, H112-3E8, H112-10C5, H11B-11B8, H11B-15G2, H11B-1C9, H11B-7E11, H11B-13D5 and Hll- 10B8 were all reactive with New 10 protein corresponding to amino 'acid residues 271 to 838 on the BVH-11-2 molecule. Six out of these 12 Mabs were directed against epitopes present in the NEW 19 protein and 3 protective Mabs recognized NEW 14.
  • Mab H112-3A4 and H112-10C5 reacted with distinct epitopes exclusive to BVH-11-2 located at the carboxyl end comprised between amino acid residues 769 and 837.
  • Mabs H11-7G11, H11-6E7 and H3-4F9 reactive with epitopes shared by pneumococcal BVH-3, BVH-11 and BVH-11-2 molecules did not succeed to protect even if given in combination with protective H112-10G9 or H112-11B8 Mab.
  • These Mabs recognized epitopes located at the amino end of the BVH- 3, BVH-11 and BVH-11-2 molecules comprising, respectively, the first 225, 228 and 226 amino acid residues.
  • the comparison of the BVH-3, BVH-11 and BVH-11-2 protein sequences revealed that a large number of amino acids were conserved in the amino end portion comprising these 225-228 residues with a- global 72.8 % identity ( Figure 32).
  • mice were injected intraperitoneally with a total of 0.2 ml' of ascites fluid 4 hours before intravenous challenge with S. pneumoniae WU2.
  • Table 10 Deduced locations of protection-conferring epitopes on BVH-11-2 molecules.
  • S . pneumoniae type 3 strain WU2 was grown in Todd Hewitt (TH) broth (Difco Laboratories, Detroit MI) enriched with 0.5% Yeast extract (Difco Laboratories) at 37°C in a 8% C0 2 atmosphere to give an OD S00 of 0.260 ( ⁇ 10 8 CFU/ml) .
  • the bacterial suspension was then aliquoted in 1 ml samples and the S ⁇ pneumoniae cells. were pelletted by centrifugation and resuspended in hybridoma culture supernatants. The bacterial suspensions were then incubated for 2 h at 4°C. Samples were washed twice in blocking buffer [PBS containing 2% bovine serum albumin (BSA) ] , and then 1 ml of goat fluorescein
  • the % Fluorescence is the number of fluorescein-labelled S_ pneumoniae cells divided by 100 and the FI value is the median fluorescence value of pneumococci treated with Mab supernatant divided by the fluorescence value of pneumococci treated with the conjugate alone or with a control unrelated Mab.
  • a FI value of 1 indicated that the Mab has not been detected at the surface of the bacteria whereas a FI value higher than 2 was considered positive when at least 10 % of the pneumococcal cells were labelled and indicated that the Mab was • reactive with cell- surface exposed epitopes.
  • Table 11 summarized the data obtained with the Mabs tested by flow cytometry.
  • This example describes the immunization of animals with peptide epitopes of BVH-3 and BVH-11-2.
  • the recombinant pSCREEN-T vector (Novagen, Madison, WI) containing DNA fragment (nucleotides 2421 to 2626 on SEQ ID NO : 5) . encoding the Mab 3A4-epitope (SEQ ID NO: 24) was transformed by electroporation (Gene Pulser II apparatus, BIO-
  • the expression of the fusion protein is controlled by the T7 promoter which is recognized by the T7 RNA polymerase (present on the ⁇ DE3 prophage, itself under the control of the lac promoter inducible by isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) .
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • the pLysS plasmid reduces the basal fusion protein expression level by coding for a T7 lysozyme, which is a natural inhibitor of the T7 RNA polymerase .
  • the transformants were grown at 37°C with 250 RPM agitation in LB broth (peptone lOg/1, yeast extract 5g/l, NaCl 5g/l) supplemented with 50mM glucose, lOO ⁇ g/ml carbenicillin and 34 ⁇ g/ml chloramphenicol, until the absorbance at 600nm reached a value of 0,7.
  • the overexpression of T7gene 10 protein- His»Tag-3A4.1 fusion protein was then induced by the addition of IPTG to a final concentration of ImM and further incubation at 25°C with 250 RPM agitation for 3 hours. Induced cells from a 800-ml culture were pelleted by centrifugation and frozen at -70°C.
  • the fusion protein was purified from the soluble cell fraction by affinity chromatography based on the binding of a six histidine residues sequence (His-Tag) to divalent cations (Ni 2+ ) immobilized on a metal chelation Ni- NTA resin (Qiagen, Mississauga, Canada) . Briefly, the pelleted cells were thawed and resuspended in Tris buffered sucrose solution (50mM Tris, 25%(w/v) sucrose) and frozen at - 70°C for 15 minutes. Cells were incubated 15 minutes on ice in the presence of 2mg/ml lysozyme before disruption by sonication. The lysate was centrifuged at 12000 RPM for 30
  • Nickel charged Ni-NTA resin QIAgen
  • Nickel charged Ni-NTA resin QIAgen
  • the fusion 3A4.1 protein was eluted with the same buffer supplemented with 250mM imidazole.
  • the removal of the salt and imidazole was done by dialysis against PBS at 4°C.
  • the protein concentration was determined with BCA protein assay reagent kit (Perce, Rockford, IL) and adjusted to 760 ⁇ g/ml.
  • mice Female CBA/N mice (National Cancer Institute) are immunized subcutaneously three times at three-week intervals with affinity purified T7genel0 protein-His»Tag-3A4.1 fusion protein or, as control, with QuilA adjuvant alone in PBS. Twelve to fourteen days following the third immunization, the mice are challenged intravenously with S_ pneumoniae WU2 strain or intranasally with P4241 strain. Samples of the S. pneumoniae challenge inoculum are plated on chocolate agar plates to determine the number of CFU and to verify the challenge dose. The challenge dose are approximalety 300 CFU.
  • the 3A4.1 protein or other tested protein is said protective when the number of mice surviving the infection or the median number of days to death is significantly greater in the 3A4.1- immunized group compared to the control mock-immunized group.
  • This example illustrates the improvement of the antibody response to pneumococci using BVH-3 fragments and variants thereof .
  • BVH-3 gene fragments designated NEW1 (encoding amino acid residues 472 to 1039 from SEQ ID NO: 6) and NEW40 (encoding amino acid residues 408 to 1039 from SEQ ID NO: 6) were amplified from the S_ pneumoniae strain SP64 by PCR using pairs of oligonucleotides engineered • for the amplification of the appropriate gene fragment.
  • Each of the primers had a restriction endonuclease site at the 5' end, 5 thereby, allowing directional in-frame cloning of the amplified product into the digested plasmid vector.
  • PCR-amplified products were digested with restriction endonucleases and ligated to linearized plasmid pET21 (Novagen) expression vector digested likewise.
  • mice Male BALB/c mice (Charles River) immunized as described earlier in example 1 were used for protection experiments against intranasal challenge with virulent S. pneumoniae P4241 strain. The mice were observed for 10 to 14 days post-infection. Data from Table 15 clearly indicate that the NEW35A molecule was equivalent to the parental NEW1 in term of protection. Interestingly, high survival rates where obtained for NEW40- and NEW56-immunized groups with 7 and 8 survivors out of 8 animals, respectively. Similarly, NEW25 comprising amino acid residues 233 to 1039 protected 7 out of 8 animals from lethal infection.
  • Table 15 Binding of mouse sera antibodies at the surface of S. pneumoniae type 3 strain WU2 as measured by flow cytometry.
  • Cytometry results are expressed as fluorescence index value where the fluorescence index is the median fluorescence value of pneumococci treated with test sera divided by the background fluorescence value of pneumococci treated with the fluorescein conjugate alone.
  • fluorescence index is the median fluorescence value of pneumococci treated with test sera divided by the background fluorescence value of pneumococci treated with the fluorescein conjugate alone.
  • all sera were used at a dilution of 1 :50 and the sera from mice immunized with BVH-3C fragment or Quil ' A adjuvant alone gave a value similar to the background value.
  • EXAMPLE 9 This example describes the cloning and expression of a chimeric deletant BVH-11-2 gene encoding, for a chimeric polypeptide corresponding to BVH-11-2 conserved protective surface-exposed epitopes present in most if not all S . pneumoniae strains.
  • BVH-11-2 gene fragments corresponding to 4 gene regions were amplified by PCR using pairs of oligonucleotides engineered to amplify fragments originating from SEQ ID NO : 5 spanning nucleotides 1662 to 1742, 1806 to 2153, 2193 to 2414 and 2484 to 2627 from S. pneumoniae strain Sp64 BVH-11-2 gene.
  • HAMJ490-HAMJ491 PCR-amplified product was purified from agarose. gel using a QIAquick gel extraction kit from QIAgen
  • the resulting NEW43 gene sequence (SEQ ID No 257) is described in Figure 33.
  • the deduced amino acid sequence of NEW43 protein (SEQ ID No 258) is described in Figure 34.
  • NEW43 -derived molecules designated VP43S and NEW86 were generated from gene amplification and cloning experiments using PCR primers described in Tables 16 and 18 and pET21 expression plasmid vector. Variants from NEW43 were generated by mutagenesis using the Quickchange Site-Directed Mutagenesis kit from Stratagene and the oligonucleotides designed to incorporate the appropriate mutation. The presence of 6 histidine tag residues on the C-terminus of the recombinant molecules simplified the purification of the proteins by nickel chromatography. The following tables 19 and 20 describe the sequences of the primers used for the mutagenesis experiments and the NEW43 variant gene products generated, respectively. Table 19. List of PCR oligonucleotide primer sets used for site-directed mutagenesis on NEW43 gene
  • This example describes the cloning and expression of chimeric genes encoding for a chimeric protein corresponding to the carboxy-terminal region of BVH-3 or variants thereof in fusion, at either the carboxyl end or the amino end, to NEW43 or variants thereof.
  • the resultant plasmid construct were confirmed by nucleotide sequence analysis.
  • the recombinant pSL301 plasmids containing a PCR product were redigested with the same endonuclease restriction enzyme for the obtention of the DNA inserts.
  • the resulting insert DNA fragments were purified and inserts corresponding to a given chimeric gene were ligated into pURV22-NdeI vector for the generation of a chimeric gene .
  • the expressed recombinant proteins were purified from supernatant fractions obtained from centrifugation of sonicated heat-induced E ⁇ coli cultures using multiple chromatographic purification steps.
  • Table 22 List of polypeptides encoded by chimeric genes comprising a BVH-3 truncate variant gene and a NEW43 or NEW43 variant gene
  • Encoded amino acids for the chimeras are expressed as the gene product, additional amino acid residues were added.
  • M is methionine
  • G is glycine
  • P is proline.
  • Table 23 List of PCR oligonucleotide primer pairs designed for the generation of the chimeric genes encoding the polypeptides listed in Table 22.
  • Table 24 List of PCR oligonucleotide primers designed for the generation of the chimeric genes encoding the polypeptides listed in Table 22.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention a trait à des polypeptides de streptocoque ainsi qu'à des polynucléotides les codant, lesquels polypeptides s'avèrent des plus utiles en tant que composants de vaccins, aux fins de la prophylaxie et du traitement d'infections par streptocoque chez des animaux. L'invention porte également sur des techniques de recombinaison permettant de produire des antigènes protéiques ainsi que sur des méthodes diagnostiques visant à détecter une infection bactérienne par streptocoque.
EP01949136A 2000-06-20 2001-06-19 Antigenes de streptocoque Withdrawn EP1303612A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10179497A EP2281891A3 (fr) 2000-06-20 2001-06-19 Antigènes de streptococcus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21268300P 2000-06-20 2000-06-20
US212683P 2000-06-20
PCT/CA2001/000908 WO2001098334A2 (fr) 2000-06-20 2001-06-19 Antigenes de streptocoque

Publications (1)

Publication Number Publication Date
EP1303612A2 true EP1303612A2 (fr) 2003-04-23

Family

ID=22792041

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01949136A Withdrawn EP1303612A2 (fr) 2000-06-20 2001-06-19 Antigenes de streptocoque
EP10179497A Withdrawn EP2281891A3 (fr) 2000-06-20 2001-06-19 Antigènes de streptococcus

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10179497A Withdrawn EP2281891A3 (fr) 2000-06-20 2001-06-19 Antigènes de streptococcus

Country Status (18)

Country Link
EP (2) EP1303612A2 (fr)
JP (2) JP5051959B2 (fr)
KR (1) KR100927767B1 (fr)
CN (2) CN101260149B (fr)
AR (1) AR033980A1 (fr)
AU (2) AU2001270381B2 (fr)
CA (1) CA2413450C (fr)
CZ (1) CZ2003154A3 (fr)
EA (1) EA006232B1 (fr)
HU (1) HU228706B1 (fr)
IL (2) IL153558A0 (fr)
MX (1) MXPA03000103A (fr)
NO (1) NO331103B1 (fr)
NZ (1) NZ553554A (fr)
PL (1) PL214229B1 (fr)
TR (1) TR200704553T2 (fr)
UY (1) UY26783A1 (fr)
WO (1) WO2001098334A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
EP1456231A2 (fr) * 2001-12-20 2004-09-15 Shire Biochem Inc. Antigenes de streptococcus
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN101378778B (zh) 2005-12-22 2013-02-06 葛兰素史密丝克莱恩生物有限公司 肺炎球菌多糖缀合物疫苗
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PT2097102E (pt) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
US20100074918A1 (en) 2007-05-02 2010-03-25 Jan Poolman Vaccine
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
CN101802198B (zh) * 2007-07-23 2016-02-17 圣诺菲·帕斯图尔有限公司 免疫原性多肽和单克隆抗体
RS54306B1 (en) 2008-04-16 2016-02-29 Glaxosmithkline Biologicals S.A. THE VACCINE
AU2009296458A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
WO2010132833A1 (fr) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Compositions vaccinales contre streptococcus et méthodes d'utilisation associées
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
NZ620441A (en) 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
KR101272351B1 (ko) * 2010-04-23 2013-06-07 이화여자대학교 산학협력단 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법
EP2680883B1 (fr) 2011-03-02 2018-09-05 Pfizer Inc Vaccin à base de pcsk9
WO2012156391A1 (fr) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccin contre le streptococcus pneumoniae
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
JP6612260B2 (ja) 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート
SI3096786T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3616716A3 (fr) 2014-01-21 2020-05-06 Pfizer Inc Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
US10668164B2 (en) 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
CN107427568B (zh) 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
PE20240927A1 (es) 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (fr) 2015-11-20 2023-10-10 Pfizer Inc. Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
ES2911490T3 (es) 2017-01-20 2022-05-19 Pfizer Composiciones inmunogénicas para su uso en vacunas antineumocócicas
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
CN118063638A (zh) 2017-09-07 2024-05-24 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
JP7369123B2 (ja) 2017-12-06 2023-10-25 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖類－タンパク質コンジュゲートを含む組成物およびその使用方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
MA54533A (fr) 2018-12-19 2022-03-30 Merck Sharp & Dohme Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
CA3159573A1 (fr) 2019-11-01 2021-05-06 Pfizer Inc. Compositions d'escherichia coli et methodes associees
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
PE20230170A1 (es) 2020-02-23 2023-02-01 Pfizer Composiciones de escherichia coli y sus metodos
CA3199094A1 (fr) 2020-10-22 2022-04-28 Pfizer Inc. Procedes de purification de polysaccharides bacteriens
JP2023546615A (ja) 2020-10-27 2023-11-06 ファイザー・インク 大腸菌組成物およびその方法
AU2021373358A1 (en) 2020-11-04 2023-06-01 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (fr) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination contre des infections à pneumocoque et à covid-19
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Inc Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
WO2023135515A1 (fr) 2022-01-13 2023-07-20 Pfizer Inc. Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
WO2023218322A1 (fr) 2022-05-11 2023-11-16 Pfizer Inc. Procédé de production de formulations de vaccin avec des conservateurs
WO2024084397A1 (fr) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination contre infections à pneumocoques et à covid-19
WO2024110827A1 (fr) 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024110839A2 (fr) 2022-11-22 2024-05-30 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
WO1996040225A1 (fr) * 1995-06-07 1996-12-19 Alberta Research Council Compositions oligasaccharidiques immunogenes et immunostimulatrices et leurs procedes de production et d'utilisations
WO1998018931A2 (fr) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Polynucleotides et sequences de streptococcus pneumoniae
BR9812525A (pt) * 1997-09-24 2000-07-25 Univ Minnesota Proteinase degradadora de complemento humano c3 de streptococcus pneumoniae
JP2002531055A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
JP2004505885A (ja) * 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
IL142017A0 (en) * 1998-09-24 2002-03-10 Univ Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
EP2050464B1 (fr) * 1998-12-21 2019-08-07 Medimmune, Inc. Protéines de streptococcus pneumoniae et fragments immunogènes pour vaccins
PT2261358E (pt) * 1998-12-23 2014-07-30 Id Biomedical Corp Quebec Antigénios de streptococcus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0198334A2 *

Also Published As

Publication number Publication date
JP5051959B2 (ja) 2012-10-17
EP2281891A3 (fr) 2011-08-17
PL214229B1 (pl) 2013-07-31
WO2001098334A2 (fr) 2001-12-27
NO331103B1 (no) 2011-10-10
HUP0301656A2 (hu) 2003-08-28
EA200201280A1 (ru) 2003-06-26
WO2001098334A3 (fr) 2002-09-06
HU228706B1 (en) 2013-05-28
EA006232B1 (ru) 2005-10-27
NO20026121D0 (no) 2002-12-19
EP2281891A2 (fr) 2011-02-09
HUP0301656A3 (en) 2004-10-28
CA2413450C (fr) 2014-02-18
CN1449446A (zh) 2003-10-15
KR20030013450A (ko) 2003-02-14
CA2413450A1 (fr) 2001-12-27
CN101260149A (zh) 2008-09-10
PL360413A1 (en) 2004-09-06
CN101260149B (zh) 2016-05-11
AU7038101A (en) 2002-01-02
IL153558A0 (en) 2003-07-06
CZ2003154A3 (cs) 2003-06-18
IL153558A (en) 2011-07-31
MXPA03000103A (es) 2003-06-19
AR033980A1 (es) 2004-01-21
JP2004501618A (ja) 2004-01-22
TR200704553T2 (tr) 2007-11-21
UY26783A1 (es) 2002-01-31
JP2012187110A (ja) 2012-10-04
JP5889103B2 (ja) 2016-03-22
AU2001270381B2 (en) 2007-05-24
NO20026121L (no) 2003-02-13
KR100927767B1 (ko) 2009-11-20
NZ553554A (en) 2008-11-28

Similar Documents

Publication Publication Date Title
AU2001270381B2 (en) Streptococcus antigens
AU2001270381A1 (en) Streptococcus antigens
US7262024B2 (en) Streptococcus antigens
KR101078919B1 (ko) 신규한 스트렙토코커스 항원
KR100771148B1 (ko) 그룹 ｂ 스트렙토코커스 항원
US20060177465A1 (en) Streptococcus antigens
US20080038268A1 (en) Streptococcus Pyogenes Antigens
US20150017684A1 (en) Streptococcus pyogenes antigens and corresponding dna fragments
EP1362106B1 (fr) Polypeptides de streptococcus pyogenes et fragments d'adn correspondants
EP1325133B1 (fr) Antigenes bvh-a2 et bvh-a3 du streptocoque du groupe b
AU2001272270B2 (en) Streptococcus pyogenes antigen
WO2004007725A9 (fr) Polypeptide de streptococcus pyogenes
AU2007207883A1 (en) Streptococcus antigens
WO2002079475A2 (fr) Antigenes streptococcus pyogenes et fragments d'adn correspondants
AU2001272270A1 (en) Streptococcus pyogenes antigen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030117

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BRODEUR, BERNARD

Inventor name: MARTIN, DENIS

Inventor name: CHARLAND, NATHALIE

Inventor name: OUELLET, CATHERINE

Inventor name: HAMEL, JOSEE

R17D Deferred search report published (corrected)

Effective date: 20020906

17Q First examination report despatched

Effective date: 20040802

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ID BIOMEDICAL CORPORATION

17Q First examination report despatched

Effective date: 20040802

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ID BIOMEDICAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101123